Skip to main content

Table 2 Demographic and clinical characteristics of patients in the anti-TNF and stem cell groups

From: Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational study

  Anti-TNF (n=39) Stem cell (n=30) p-value
Age, median (IQR) 31.0 (25-34) 26.0 (20-30.25) 0.028
Sex
 Male 29 (74.4%) 14 (46.7%) 0.019
 Female 10 (25.6%) 16 (53.3%)  
Montreal classification
 Age at onset
  A1 (≤16yr) 15 (38.5%) 6 (20.0%) 0.098
  A2 (17-40yr) 24 (61.5%) 24 (80.0%)  
  A3 (≥41yr) 0 (0.0%) 0 (0.0%)  
 Location
  L1 (Ileum) 4 (10.3%) 8 (26.7%) 0.171
  L2 (Colon) 3 (7.7%) 3 (10.0%)  
  L3 (Ileocolon) 32 (82.1%) 19 (63.3%)  
 Behavior
  B1 (Non-stricturing, non-penetrating) 12 (30.8%) 20 (66.7%) 0.002
  B2 (Stricturing) 6 (15.4%) 6 (20.0%)  
  B3 (Penetrating) 21 (53.8%) 4 (13.3%)  
Albumin, mean±SD (g/dL) 3.36±0.48 4.05±0.42 <0.001
CRP, mean±SD (mg/dL) 3.03±3.04 0.56±0.74 <0.001
Fistula type
 Simple 13 (33.3%) 6 (20.0%) 0.219
 Complex 26 (66.7%) 24 (80.0%)  
Multiple fistula 15 (38.5%) 13 (43.3%) 0.683
Proctitis 19 (48.7%) 10 (33.3%) 0.199
Stricture 1 (2.6%) 2 (6.7%) 0.407
Abscess 18 (46.2%) 17 (56.7%) 0.387
Medical treatment
 Immunomodulators 16 (41.0%) 15 (50.0%) 0.458
 Steroids 2 (5.2%) 0 (0.0%) 0.208
Smoking
 Current smoker 4 (10.3%) 1 (3.3%) 0.355
 Ex-smoker 8 (20.5%) 4 (13.3%)  
Previous fistula OP 37 (94.9%) 30 (100%) 0.208
No. previous fistula OP, mean±SD (times) 3.24±1.89 2.17±1.29 0.010
Interval from seton treatment to anti-TNF or stem cell therapy, mean±SD (months) 1.03±0.93 16.13±16.01 <0.001
Disease duration, mean±SD (years) 9.37±6.13 6.10±4.88 0.018
  1. Results are presented as n (%) unless otherwise indicated.
  2. IQR Inter-quartile range, TNF tumor necrosis factor, SD Standard deviation, CRP C-reactive protein, OP operation